Clinical Trial Update: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

View source ↗

Summary

Pfizer-sponsored trial evaluating axitinib in patients with advanced renal cell carcinoma after failure of first-line therapy has been withdrawn (no longer avai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: NO_LONGER_AVAILABLE